Vincent C. Lombardi, Ph.D. began his work in CFS, as an undergraduate in the field of Biostatistics, characterizing T-cell populations in CFS patients. He later continued to work in CFS-related research in the laboratory of Dr. Robert Suhadolnik at Temple University, studying the interferon regulated RNase L antiviral pathway and its involvement in CFS. Dr. Lombardi completed his graduate degree at the University of Nevada receiving his Ph.D. in Biochemistry in 2005. The primary focus of his Ph.D. thesis was the isolation and characterization of novel diuretic neuro-peptides. Prior to the completion of his graduate degree he co-founded the specialty clinical laboratory, Redlabs, U.S.A., Inc. This clinical laboratory, which later became VIPDx, was formed to serve doctors and their patients who suffer from CFS. Dr. Lombardi served as the Director of Operations as well as the leader of laboratory research and development for new diagnostics in the clinical laboratory.Or met Mikovits first with Silverman?
Upon joining WPI July 1, 2007, Dr. Lombardi's research effort focused on the inflammatory component of CFS and its relationship to the development of lymphoma in CFS patients. It was at this time that Dr. Lombardi established his collaboration with Robert Silverman, Ph.D., of the Cleveland Clinic, the world's leading authority regarding the RNase L antiviral pathway. Dr. Silverman had recently made the discovery of XMRV in RNase L deficient cancer patients. Dr. Lombardi's research on the association of the RNase L pathway in CFS patients, and discussions with Dr. Silverman prompted him to begin the search for XMRV in CFS.
In October 2007, Mikovits attended a prostate-cancer meeting near Lake Tahoe, Nevada, where she met Robert Silverman, a virologist at the Cleveland Clinic in Ohio. …At the meeting, Silverman was presenting research linking XMRV to deficiencies in a virus-defence pathway.So who was it? Professor Vincent Plum or Colonel Judy Mustard?